Table 2.
Summary of current clinical trials using CAR NK cells in hematological cancers.
| Sources of NK Cells | Disease | Receptor Target | Trial Number (NCT) | Phase |
|---|---|---|---|---|
| NK92 | Lymphoma and Leukemia | CD7 | 02742727 | I/II |
| Lymphoma and Leukemia | CD19 | 02892695 | I/II | |
| AML r/r | CD33 | 02944162 | I/II | |
| MM r/r | BCMA | 03940833 | I/II | |
| B-cell lymphoma r/r | CD19 | 03690310 | I | |
| CB-derived NK cells | ALL, CLL and NHL r/r | CD19 | 03056339 | I/II |
| B-cell lymphoma | CD19 | 03579927 | I/II | |
| unknown | B-cell lymphoma r/r | CD19+CD22 | 03824964 | I |
| PB NK cells | ALL | CD19 | 01974479 | I |
| ALL | CD19 | 00995137 | I | |
| unknown | B-cell lymphoma r/r | CD22 | 03692767 | I |
| iPSC-derived NK cells | B-cell lymphoma r/r | CD19 | 03824951 | I |
Abbreviations used: ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; r/r, refractory/relapsed; CB, cord blood; iPSC, induced pluripotent stem cells; PB, peripheral blood; BCMA, B cell maturation antigen.